TOP-N53

Topadur Pharma AG · Phase 2 active Small molecule

At a glance

Generic name	TOP-N53
Sponsor	Topadur Pharma AG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TOP-N53 CI brief — competitive landscape report
TOP-N53 updates RSS · CI watch RSS
Topadur Pharma AG portfolio CI